Published: 2022-08-24

Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio and one year survival of lung cancer in Sanglah hospital

Pande Made Andikayasa, Ketut Suryana, Ida Ayu Jasminarti Dwi Kusumawardani, Ni Wayan Candrawati, Ni Luh Putu Eka Arisanti, I. Gede Ketut Sajinadiyasa, Ida Bagus Ngurah Rai


Background: Lung cancer is ranked third as the most common cancer in Indonesia. The one-year survival rate of advanced-stage non-small cell lung carcinoma (NSCLC) patient is quite low, that is 24.6%. Effective and inexpensive prognostic markers need to be further studied due to an increasing incidence of cancer. Inflammation plays an important role in tumorigenesis and research showed an association of NLR and PLR values with poor prognosis in patients with various solid tumors, but current cut off values still vary. This study wanted to determine the value of NLR, PLR and their relationship with the survival rate of advanced stage NSCLC patients at Sanglah hospital.

Methods: A retrospective cohort study using the medical record of 96 advanced-stage NSCLC patients who underwent treatment since January 2018 in Sanglah hospital, was closely monitored for a year since diagnosed. Analysis was performed with ROC, Kaplan Meier analysis, log rank test, and time independent cox regression model.

Results: The one-year survival rate of advanced stage NSCLC patient is 14.6%, with median survival 3.26 months. Cut off NLR> 3.37, median survival 2.66, p=0.00. Cut off PLR>178.55, median survival 3.26, p=0.35. Multivariate analysis showed that NLR, HR=2.75 and performance status, HR=1.78 were associated with survival.

Conclusions: NLR with cut off >3.37 is associated with one-year survival rate of advanced-stage NSCLC patient. PLR did not have any significant association with one-year survival rate of advanced-stage NSCLC patient.


Cut off, NLR, PLR, Survival, Lung cancer

Full Text:



National Comprehensive Cancer Network. Non-small cell lung cancer. NCCN Clin Pract Oncol. 2019;3:1-225.

Ministry of Health of Indonesia. Infodatin cancer, 2015. Available at: https://pusdatin. Accessed on 20 March 2022.

Fawziah Ana, Sari NK, Uyainah A, Soetandyo N, Dewiasty E. One-year survival of elderly non-small cell lung carcinoma stage IIIb/IV undergoing chemotherapy compared to non-chemotherapy. Ina J Chest Crit and Emerg Med. 2015;2(2):54-60.

Zhao S, Zhang Z, Zhang Y, Hong S, Zhou T, Yang Y, et al. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer. Int J Cancer. 2019;144(11):2854-66.

Fan H, Shao Z, Xiao Y, Xie Z, Chen W, Xie H, et al. Incidence and survival of non-small cell lung cancer in Shanghai : a population-based cohort study. BMJ Open. 2015;5:e009419.

Schwarzkopf L, Wacker M, Holle R, Leidl R, Günster C, Adler JB, et al. Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens. Lung Cancer. 2015;90(2):274-80.

Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS One. 2018;13(2):1-13.

Yann A, Stephane O, Marie A, Pauline T, Elaidi R, Thibault C, et al. Optimal cut-off for neutrophil-to-lymphocyte ratio : Fact or Fantasy ? A prospective cohort study in metastatic cancer patients. PLoS One. 2018;4(13):1-13.

Bowen RC, Ann N, Little B, Harmer JR, Ma J, Mirabelli LG, et al. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. Oncotarget. 2017;8(19):32171-89.

Liu D, Jin J, Zhang L, Song J, Li W. The neutrophil to lymphocyte ratio may predict benefit from chemotherapy in lung cancer. Cell Physiol Biochem. 2018;46:1595-605.

Ozyurek BA, Ozdemirel TS, Ozden SB, Erdoan Y, Kaplan B, Kaplan T. Prognostic value of the neutrophil to lymphocyte ratio (NLR) in lung cancer cases. Asian Pac J Cancer Prev. 2017;18(5):1417-21.

Ramadhaniah F, Khairina D, Dian TS, Evlina SAM. Overview of lung cancer patients at Dharmais cancer hospital (RSKD) in 2008-2012. J Respir Indonesian. 2019;39(1):31-9.

Kang KH, Efird JT, Sharma N, Yang M, Dowlati A, Linden P, et al. Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer. Future Oncol. 2017;3:1-10.

Faot NE, Pradjoko I. Neutrophil lymphocyte ratio before chemotherapy and the objective response to chemotherapy of lung cancer patients with platinum-based chemotherapy. J Respira Indo. 2017;37(4):293-8.

Praptini M. Effect of age on one-year survival of non-small cell lung cancer treated at the Cipto Mangunkusumo Hospital and Dharmais cancer hospital. Faculty Med Univ Indonesia. 2014.

Napirah MR, Rahman A, Tony A. Factors related to the utilization of health services in the working area of the Tambarana public health center, Poso Pesisir Utara District, Poso Regency. J City Builder. 2016; 4(1):29.

Templeton AJ, Mcnamara MG, eruga B, Vera-badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors : a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):12-8.

Wang J, Kalhor N, Hu J, Wang B, Chu H, Zhang B, et al. Pretreatment neutrophil to lymphocyte ratio is associated with poor survival in patients with stage I-III non-small cell lung cancer. PLoS One. 2016;4:1-16.

Phan TT, Ho TT, Nguyen HT, Nguyen HT, Tran TB, Nguyen ST. The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI. Int J Gen Med. 2018;5:423-30.

Berardi R, Rinaldi S, Santoni M, Newsom-davis T, Tiberi M, Morgese F, et al. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy. Oncotarget. 2016;7(18):21-8.

Gu X, Tian T, Tian X, Zhang X. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer : a meta- analysis. Nat Publ Gr. 2015;7:1-9.

Mandaliya H, Jones M, Oldmeadow C, Nordman IIC. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl Lung Cancer Res. 2019;8(6):886-94.

Kos M, Hocazade C, Kos FT, Uncu D, Karakas E, Dogan M. Prognostic role of pretreatment platelet lymphocyte ratio in patients with non-small cell lung cancer. Wien Klin Wochenschr. 2015;5:1-6.

Minkov P, Gulubova M, Chilingirov P, Ananiev J. The position of neutrophils-to-lymphocytes and lymphocytes-to-platelets ratio as predictive markers of progression and prognosis in patients with non-small cell lung cancer. J Med Sci. 2018;6(8):1857-9655.

Haryati H, Diany H. Platelet-to-lymphocyte ratio (PLR) profile and neutrophil-to-lymphocyte ratio (NLR) in lung cancer patients in Ulin General Hospital Banjarmasin 2017-2018. Berk Kedokt. 2020; 16(1):25.

Sabrkhany S, Kuijpers MJE, van Kuijk SMJ, Sanders L, Pineda S, Olde Damink SWM, et al. A combination of platelet features allows detection of early-stage cancer. Eur J Cancer. 2017;80:5-13.

Catani MV, Savini I, Tullio V, Gasperi V. The “janus face” of platelets in cancer. Int J Mol Sci. 2020;21(3): 23-8.

Haemmerle M, Stone RL, Minister DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. Cancer Cells. 2018; 33(6):965-83.